BDR 531
Alternative Names: BDR-531Latest Information Update: 02 Nov 2022
At a glance
- Originator MDimune
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 14 Oct 2022 BDR 531 is available for licensing as of 14 Oct 2022. http://www.mdimune.com/en/ (MDimune pipeline, October 2022)
- 14 Oct 2022 MDimune enters into a collaborative agreement with an Unknown organization (MDimune pipeline, October 2022)
- 14 Oct 2022 MDimune has patent protection for BioDrone® in USA, Europe, Japan, Korea and China before October 2022 (MDimune pipeline, October 2022)